SCHEMBL12598516

SCHEMBL12598516

Cc1ccc(S(=O)(=O)Nc2cccc3cccnc23)cc1C(N)=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 8/20 0.64
▸ TDP1 Q9NUW8 8/20 0.63
▸ KMT2A Q03164 6/20 0.63
▸ AGTR1 P30556 2/20 0.63
▸ MITF O75030 1/20 0.63
▸ S1PR4 O95977 1/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ LMNA P02545 1/20 0.63
▸ MAPT P10636 1/20 0.63
▸ S1PR1 P21453 1/20 0.63
▸ OPRK1 P41145 1/20 0.63
▸ HTT P42858 1/20 0.63
▸ CKS1B P61024 1/20 0.63
▸ SKP2 Q13309 1/20 0.63
▸ NPSR1 Q6W5P4 1/20 0.63
▸ GLO1 Q04760 7/20 0.62
▸ MEN1 O00255 5/20 0.62
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ G6PD P11413 1/20 0.57
▸ NFKBIA P25963 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30925435 0.85 SLC40A1 (0.74) SLC40A1TDP1KMT2AAGTR1MITF
SCHEMBL16750883 0.85 SLC40A1 (0.74) SLC40A1TDP1KMT2AAGTR1MITF
SCHEMBL13485919 0.81 GLO1 (0.80) SLC40A1TDP1KMT2AAGTR1MITF
SCHEMBL30925457 0.79 SLC40A1 (0.59) SLC40A1TDP1KMT2AAGTR1MITF
SCHEMBL27214288 0.79 SLC40A1 (0.59) SLC40A1TDP1KMT2AAGTR1MITF
SCHEMBL11973852 0.78 SLC40A1 (1.00) SLC40A1TDP1KMT2AAGTR1MITF
SCHEMBL4471796 0.78 TDP1 (1.00) SLC40A1TDP1KMT2AAGTR1MITF
SCHEMBL12598513 0.78 SMN1; SMN2 (0.59) KMT2AALDH1A1LMNAMEN1SMN1; SMN2
SCHEMBL30925437 0.77 SLC40A1 (0.74) SLC40A1TDP1KMT2AAGTR1MITF
SCHEMBL27214241 0.77 SLC40A1 (0.74) SLC40A1TDP1KMT2AAGTR1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011072174-A1 THERAPEUTICALLY ACTIVE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER CHARACTERIZED AS HAVING AN IDH MUTATION AGIOS PHARMACEUTICALS, INC. (US) 2011-06-16 — — WO disclosed
Send feedback